SageView Advisory Group LLC purchased a new position in Humana Inc. (NYSE:HUM - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,364 shares of the insurance provider's stock, valued at approximately $346,000.
Several other institutional investors also recently modified their holdings of HUM. Transcend Capital Advisors LLC increased its position in Humana by 399.7% during the fourth quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider's stock valued at $924,000 after acquiring an additional 2,914 shares during the last quarter. FNY Investment Advisers LLC grew its position in Humana by 6,647.5% during the fourth quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider's stock valued at $6,916,000 after buying an additional 26,856 shares during the period. Retirement Systems of Alabama raised its position in Humana by 735.9% in the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider's stock worth $55,563,000 after acquiring an additional 192,801 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Humana by 7.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider's stock worth $244,811,000 after purchasing an additional 65,735 shares in the last quarter. Finally, Secure Asset Management LLC bought a new stake in Humana during the fourth quarter valued at about $244,000. 92.38% of the stock is owned by hedge funds and other institutional investors.
Humana Trading Down 6.4 %
HUM traded down $16.99 during trading hours on Monday, reaching $247.49. 433,497 shares of the company's stock traded hands, compared to its average volume of 1,754,860. The firm has a 50-day moving average price of $265.90 and a 200 day moving average price of $270.22. The firm has a market capitalization of $29.87 billion, a PE ratio of 24.95, a PEG ratio of 2.05 and a beta of 0.62. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46.
Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, sell-side analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.
Humana Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.43%. The ex-dividend date is Friday, June 27th. Humana's payout ratio is 35.58%.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on the stock. Barclays increased their target price on shares of Humana from $270.00 to $322.00 and gave the stock an "equal weight" rating in a report on Friday, April 11th. Morgan Stanley dropped their price target on Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. StockNews.com raised shares of Humana from a "hold" rating to a "buy" rating in a report on Monday, April 7th. Guggenheim initiated coverage on shares of Humana in a report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price target on the stock. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Seventeen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $284.90.
Check Out Our Latest Analysis on Humana
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
